Notable Downgrades: 3D Systems (DDD), Qihoo (QIHU), Tiffany & Co. (TIF), AstraZeneca (AZN)

Analysts at Gabelli & Co. downgraded 3D Systems Corporation (DDD) from ‘Buy’ to ‘Hold’ in a research report issued to clients on Tuesday. The name was also cut to ‘Underweight’ from ‘Neutral’ at JP Morgan (JPM).

On valuation measures, 3D Systems stock it’s trading at a forward P/E multiple of 25.77x. The t-12-month revenue at 3D Systems Corp. is $670.24 million. DDD’s ROE for the same period is (4.5%).

Shares of the $1.42 billion market cap company are down 46.93% year-over-year ; up 66.28% year-to-date.

3D Systems Corp., currently with a median Street price target of $10.50 and a high target of $16, dropped $1.82 to $12.63 in recent trading.

Qihoo 360 Technology Co. Ltd. (QIHU) was downgraded from ‘Buy’ to ‘Hold’ at Stifel. The firm said shares have reached its previous target price of $75. The also said they expect the company to complete its go private transaction as early as the end of April 2016.

Shares have traded today between $74.61 and $75.07 with the price of the stock fluctuating between $41.64 to $75.34 over the last 52 weeks.

Qihoo 360 Technology Co. Ltd. shares are currently changing hands at 36.39x this year’s forecasted earnings, compared to the industry’s 16.79x earnings multiple. Ticker has a t-12 price/sales ratio of 5.69. EPS for the same period registers at $2.05.

Shares of Qihoo have lost $0.51 to $74.69 in morning trading on Tuesday, giving it a market cap of roughly $9.2 billion. The stock traded as high as $75.34 in March 14, 2016.

Citigroup (C) reported on Tuesday that they have lowered their rating for Tiffany & Co. (TIF). The firm has downgraded TIF from ‘Buy’ to ‘Neutral’.

Tiffany & Co. recently traded at $69.75, a loss of $2.11 over Monday’s closing price. The name has a current market capitalization of $8.94 billion.

As for passive income investors, the company pays shareholders $1.60 per share annually in dividends, yielding 2.23%. Five year average dividend yield currently stands at 1.71%.

AstraZeneca PLC (AZN) had its rating lowered from ‘Buy’ to ‘Hold’ by analysts at Jefferies on Tuesday.

Currently there are 14 analysts that rate AZN a ‘Buy’, 3 analysts rate it a ‘Sell’, and 14 rate it a ‘Hold’.

AZN was down $0.75 at $28.60 in late morning trading, moving within a 52-week range of $ to $. The name opened at $28.74.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.